Alaric DeArment
Reporter

Latest From Alaric DeArment
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
GSK Antibody Appears Effective In Older COVID-19 Patients
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
Lilly’s Tirzepatide Effective, But Tolerability Still A Limitation
Tirzepatide’s efficacy seems to outweigh tolerability concerns at the lower doses, but the highest dose may be relegated to niche use.
After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.